0001818382-23-000191.txt : 20231212
0001818382-23-000191.hdr.sgml : 20231212
20231212160917
ACCESSION NUMBER: 0001818382-23-000191
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231208
FILED AS OF DATE: 20231212
DATE AS OF CHANGE: 20231212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Niklason Laura E
CENTRAL INDEX KEY: 0001878075
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39532
FILM NUMBER: 231481332
MAIL ADDRESS:
STREET 1: 35 WILSHIRE ROAD
CITY: GREENWICH
STATE: CT
ZIP: 06831
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Humacyte, Inc.
CENTRAL INDEX KEY: 0001818382
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 851763759
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2525 EAST NORTH CAROLINA HIGHWAY 54
CITY: DURHAM
STATE: NC
ZIP: 27713
BUSINESS PHONE: 919-313-9633
MAIL ADDRESS:
STREET 1: 2525 EAST NORTH CAROLINA HIGHWAY 54
CITY: DURHAM
STATE: NC
ZIP: 27713
FORMER COMPANY:
FORMER CONFORMED NAME: Alpha Healthcare Acquisition Corp.
DATE OF NAME CHANGE: 20200716
4
1
wk-form4_1702415348.xml
FORM 4
X0508
4
2023-12-08
0
0001818382
Humacyte, Inc.
HUMA
0001878075
Niklason Laura E
2525 EAST NORTH CAROLINA HIGHWAY 54
DURHAM
NC
27713
1
1
0
0
President, CEO and Director
0
Stock Options (right to buy)
2.80
2023-12-08
4
A
0
803000
0
A
2033-12-08
Common Stock
803000
803000
D
Stock Options (right to buy)
10.28
2023-12-11
4
A
0
525
0
A
2023-12-11
2030-12-14
Common Stock
525
2100
D
The first 25% of the option becomes exercisable on December 8, 2024, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2027.
On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application ("BLA") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021. On December 11, 2023 Humacyte submitted a BLA to the FDA. Accordingly, columns 5 and 7 of Table II report the number of securities equal to one-fifth of the 12/14/2020 option grant.
/s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact
2023-12-12